NCT02359227

Safety Study of Cenderitide in Stable Chronic Heart Failure

A Study Assessing the Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of Open-Label, Continuous, Stepwise, Dose Increasing, Subcutaneous Infusion of Cenderitide Via the Insulet Drug Delivery System in Subjects With Stable, Chronic Heart Failure

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: Capricor Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Planned enrollment is approximately twelve subjects with stable chronic heart failure. Enrolled subjects will receive up to eight sequential days of continuous, stepwise, dose increasing, subcutaneous (SQ) infusions of open-label cenderitide via the Insulet Drug Delivery System. Planned infusion rates of cenderitide will be administered to subjects continuously during four, 48-hour infusion periods.

Conditions

• Heart Failure

Interventions

Type	Name	Description
DRUG	Cenderitide	Cenderitide is a dual receptor natriuretic peptide.

Timeline

• Start date: 2015-01-01
• Primary completion: 2015-04-02
• Completion: 2015-04-02
• First posted: 2015-02-09
• Last updated: 2020-02-11

Locations

1 site across 1 country: United States